Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

Abstract: Provided are a measurement sample diluent that enables the measurement of the proportion of HbA1c in the total Hb molecules in a measurement sample (HbA1c (%)), with high sensitivity, high accuracy, and high correlation with HPLC without being affected by the length of time required to mix a measurement sample with the measurement sample diluent and to drop the mixture onto an immunochromatographic specimen for measuring HbA1c; and a kit containing the measurement sample diluent. The present invention relates to a measurement sample diluent for immunochromatography for quantifying the proportion of hemoglobin A1c in the total hemoglobin molecules in a measurement sample (hemoglobin A1c (%)); and the measurement sample diluent is an aqueous solution that contains a non-ionic surfactant, an anionic surfactant, and a buffer.

Abstract: This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

Abstract: The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNFR1, PIGF2, Activin A, uE3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.

Abstract: An object of the present invention is to provide a kit in which a quantitative determination of a substance to be measured in a biological sample can be carried out with high accuracy, even in a case where the substance to be measured includes a plurality of substances having different structures.

Abstract: In one embodiment, the present invention relates to a method for establishing a solvent correction curve as well as using the curve for obtaining a corrected sensorgram or corrected report points from a sensorgram of an analyte. In another embodiment, the present invention provides an analytical system for studying molecular interactions, which comprises computer processing means including program code means for performing the steps of the methods. Also provided is a computer program product comprising program code means stored on a computer readable medium or carried on an electrical or optical signal for performing the steps of the methods.

Abstract: In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.

Abstract: Methods, systems and kits are described herein for detecting the results of an assay. In particular, the methods, systems and devices of the present disclosure rely on a difference between the diffusion rates of a reporter molecule and an analyte of interest in order to quantify an amount of analyte in a microfluidic device. The analyte may be a secreted product of a biological micro-object.

Abstract: This application relates to assays, devices, and methods for conducting highly sensitive assays that employ two binding agents and are useful in detecting specific targets such as antigens. These devices and methods provide the ability to detect minute amounts of the specific target with reduced risk of false positive results.

Abstract: A detection kit for quickly detecting a lead content lead a sample is provided, and belongs to the technical field of medical in vitro immunoassay. The kit includes a detection card and a quality control; the detection card includes a bottom plate, and a sample pad, a glass fiber membrane, a nitrocellulose membrane and an absorbent paper which are arranged on the surface of the bottom plate sequentially from a loading end. The provided kit has advantages of having simple preprocessing, having no need of digestion, and being economic, fast and convenient, and the like, can realize storage at room temperature, a rapid speed, a high throughout, a low instrument cost, simple and convenient operations, single-person packaging, and detection at any time, which greatly improves the simplicity and convenience of clinical use.

Abstract: Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.

Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.

Abstract: This invention is directed to compositions and methods for detecting proteinopathies.

Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

Abstract: A liquid storage and release chip provided according to the present application includes a structural layer and an elastic cover sheet. An end surface of one side of the structural layer is provided with a liquid storage cell and a liquid quantitation cell, the liquid storage cell and the liquid quantitation cell are separated by a common partition wall, and the partition wall is provided with a valve opening passing through end surfaces of two sides of the structural layer. The elastic cover sheet is attached to the structural layer and covers the liquid storage cell, the liquid quantitation cell and the valve opening in a sealed manner, and the valve opening allows a spool to be inserted in the valve opening in a sealed manner to push up a portion, covering the valve opening, of the elastic cover sheet.

Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, isolated polynucleotide segment encoding the isolated antibodies and/or antigen-binding fragments thereof, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods, device compositions, and pharmaceutical compositions applied in theragnosis of IS-related diseases.

Abstract: Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps: Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.

Abstract: Rather than rely on variation from physician to physician and limited imaging information for assessing plaque vulnerability of a patient, medical imaging and other information are used by a machine-implemented classifier to predict plaque rupture. Anatomical, morphological, hemodynamic, and biochemical features are used in combination to classify plaque.

Abstract: An apparatus and method for characterizing a target, e.g., microbial samples or biological toxins, includes labeling the target with a biomolecular recognition construct and measuring an atomic-spectra signal of the biomolecular recognition construct. The method can include heating the labeled target before measuring the atomic-spectra signal. The atomic-spectra signal can be measured by performing laser-induced breakdown spectroscopy. The atomic-spectra signal can be measured by performing spark induced breakdown spectroscopy. The biomolecular recognition construct can be prepared by tagging a biological scaffolding with a metal atom or ion. In an aspect in which the target includes a microbial sample, the biological scaffolding can include an antibody against epitopes present on bacterial surface, the antibody linked to a heavy metal. In an aspect in which the target includes a biological toxin, the biological scaffolding can include an antibody against the biological toxin linked to heavy metals.

Abstract: A reactive antibacterial compound is represented by formula (I) or (II): wherein R1 represents OCN-L-NHCOOR?, OCN-L-NHCONHR?, OCN-L-NHCOSR?, OCN-L-COOR?, or OCN-L-COONHR?. G1 represents OCN-M-NHCOOG?, OCN-M-NHCONHG?, OCN-M-NHCOSG?, OCN-M-COOG?, or OCN-M-COONHG?. L, M, R? and G? independently for each occurrence represent divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by up to 18 heteroatoms. R4 and G4 independently for each occurrence represent a divalent alkyl and cycloalkyl having from 1 to 18 carbon atoms, optionally substituted by up to 18 heteroatoms. G2 and G3 independently for each occurrence represent —H, —F, —Cl, —Br, —I, —OCH3, —OCH2CH3, —OPr, —CN, —SCN, —NO, —NO2, a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 7 carbon atoms. Z and X independently for each occurrence represent —COO, —SO3, or —OPO2OR5. R5 represents a monovalent unsubstituted or substituted alkyl, cycloalkyl, or aryl having from 1 to 6 carbon atoms.

Abstract: The present disclosure relates to acetaminophen protein adducts and methods of diagnosing acetaminophen toxicity using the acetaminophen protein adducts. The present disclosure provides acetaminophen (APAP)-protein adducts and methods of detecting acetaminophen-induced toxicity in a subject using APAP-protein adducts. One aspect of the present disclosure provides an APAP-protein adduct for diagnosing acetaminophen-induced toxicity. According to the present disclosure, the inventors have identified proteins that are modified by N-acetyl-pbenzoquinoneimine (NAPQI) in subjects with acetaminophen-induced toxicity. Non-limiting examples of proteins modified by NAPQI include betaine-homocysteine S-methyltransferase 1, cytoplasmic aspartate aminotransferase, 1,4-alpha-glucan branching enzyme, formimidoyltransferase-cyclodeaminase, and dystrophin.

Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL™ (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6.

Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.

Abstract: An apparatus for detecting liquids or substances from liquids in spatially separate reaction zones using a plug-in module or a chip card for rapid immunological tests, for example, with the help of a reading device. The liquids or substances from liquids are detected by a sensor array and on which at least one diaphragm is arranged. Individual sensors are spatially separated from each other on a plane by means of walls. The diaphragm is filled with liquid that is to be analyzed. Sealed reaction chambers are created when pressure is applied to the diaphragm. Pores in the diaphragm are completely closed in the zone of the walls while the pores are merely reduced in size and liquid can continue to be exchanged in zones directly above the sensors. No liquid can be exchanged between adjacent reaction chambers as long as pressure is applied to and compresses the diaphragm.

Abstract: The present invention relates to a method for determining the propensity of a fluid for calcification characterized by the following steps: (i) adding a soluble calcium salt and a soluble phosphate salt to a sample of the fluid; (ii) incubating the sample at conditions allowing the formation of calciprotein particles (CPPs); and (iii) determining one or more of the following: (a) the rate of the formation of primary and/or secondary CPPs; (b) the amount of primary and/or secondary CPPs; and/or (c) the rate of the transition of primary CPPs into secondary CPPs, wherein an increase in one or more of (a), (b) and/or (c) of step (iii) indicates an increased propensity of the fluid for calcification.

Abstract: The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvates, and/or esters thereof. These compounds are useful for treating itch or a pruritic condition. The present invention also includes compositions comprising the present compounds and methods of treating a pruritic condition. Furthermore, the present invention provides methods for preparing the compounds.

Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.

Abstract: The invention relates to monoclonal antibodies which are reactive with an epitope in the polypeptide represented by amino acid sequence 236 to 251 or 264 to 279 of the human CGA amino acid sequence. The invention further relates to the use of these monoclonal antibodies in an immunoassay for CGA, to immunoreagents comprising any of these two antibodies, and to test kits for the determination of CGA containing immunoreagents based on both of the monoclonal antibodies.

Abstract: The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals.

Abstract: The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, wherein each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease.

Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.

Abstract: Compositions, methods and kits for determining progesterone levels in mares are disclosed.

Abstract: A sorptive extraction layer for immobilized liquid extraction of target molecules preferably from biological samples is disclosed. The sorptive extraction layer is mainly composed of ethylene-acrylate-copolymer. Preferably, microplate wells are at least partially coated with such a sorptive extraction layer. There is also disclosed a method of extracting target molecules preferably from biological samples. According to this method, immobilized liquid extraction is carried out with a sorptive extraction layer which is mainly composed of ethylene-acrylate-copolymer.

Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.

Abstract: The present invention discloses a method improving the sensitivity of competitive immunoassay, mainly, the small molecular substances for detection first react with the antibody/receptor sufficiently, then react with the second molecules, which locates on the solid phase and participates the competitive reactions, in a short time, which may greatly improve the sensitivity of competitive immunoassay. The present invention owns an easy operation method and a low cost, does not require expensive equipments or professional technological personnel, also, it owns a high sensitivity and adapts to a plurality of immunoassay methods.

Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.

Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a verterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.

Abstract: Devices, systems, and methods for detecting molecules of interest within a collected sample are described herein. In certain embodiments, self-contained sample analysis systems are disclosed, which include a reusable reader component, a disposable cartridge component, and a disposable sample collection component. In some embodiments, the reader component communicates with a remote computing device for the digital transmission of test protocols and test results. In various disclosed embodiments, the systems, components, and methods are configured to identify the presence, absence, and/or quantity of particular nucleic acids, proteins, or other analytes of interest, for example, in order to test for the presence of one or more pathogens or contaminants in a sample.

Abstract: The invention provides a modified form of saturation assay, which is based on the measurement of a free or unbound labelled reagent fraction (such that there is an increase in signal in the presence of analyte) and employs trapping zones to concentrate said unbound or free labelled fraction to avoid loss of sensitivity. Preferably, the assay is a membrane assay.

Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.

Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: The present invention relates to compositions, kits, and methods for providing a prognosis and/or determining a treatment course of action in a subject diagnosed with breast cancer. In particular, the present invention relates to gene expression signatures useful in the prognosis, diagnosis, and treatment of breast cancer.

Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonist antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.

Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.

Abstract: One aspect of the present disclosure relates to a calorimeter for detecting the presence of a target analyte in a fluid sample. The calorimeter can include a substrate, a hermetically-sealed, thermally decoupled central reaction zone associated with the substrate, at least one droplet transport region, and detection electronics. The at least one droplet transport region can be associated with the substrate and configured to merge a reagent droplet with a sample droplet including the fluid sample to form a reaction droplet in the central reaction zone. The detection electronics can be in electrical and/or thermal communication with the central reaction zone and associated with the substrate. The calorimeter can be configured to detect a heat of reaction produced by a reaction event between the target analyte and a capture reagent upon formation of the reaction droplet.

Abstract: Embodiments of the invention include methods for detecting and determining the concentrations of macro and small molecules, including bio-molecules, in a liquid or gaseous sample.

Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.